Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2009

Lonza Launches Cells on Demand Services for Cell Culture and Transfection

  • Lonza launched Cells on Demand™ Cell Culture and Transfection Services as a new offering for assay-ready cells for cell-based screening. Lonza says the new services cover bulk cell production, transfection services, cell-isolation services, and media production.

    Large-scale manufacturing is offered for cell lines, transfected cells, and primary cells including Clonetics® primary cells and Poietics® stem cells. The transfection services include expertise with Amaxa® Nucleofactor® technology for generating stable clones and transiently transfected cells as well as Nucleofection® Protocol Optimization and small-scale protein production.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »